HOME> product

Emirodatamab

Sales marketing Email：peptidedb@qq.com
Bioactivity Emirodatamab (AMG-427) is a half-life extended anti-FLT3/CD3 bispecific T-cell engager. Emirodatamab induces high cytotoxicity of primary AML blasts with increased FLT-3 expression. Combining Emirodatamab with an anti-PD-1 antibody can increase T-cell-dependent cellular cytotoxicity (TDCC). Emirodatamab can be used for research of relapsed or refractory AML[1][2].
CAS 2449199-61-3
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Reference [1]. Brauchle B, et al. Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia. Mol Cancer Ther. 2020 Sep;19(9):1875-1888. [2]. Morse JW, et al. Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets. Expert Opin Investig Drugs. 2023 Feb;32(2):107-125.
How to place a order： 1) Contact us at: Whatsapp:+86-(0)-18753388868 or peptidedb@qq.com;
2) Provide us peptides information including Sequence, Purity, Quantity and modification(If necessary, we agree to sign confidential agreement with you before you provide these information), we will make you a quotes within 30 minutes;
3) Place us a purchaser order, we can send you a sales contract too if you need;
4) Start synthesis, and we will inform you the updates of synthesis in time;
5) Arrange shippment, HPLC analysis, MS spectrum will be shipped along the peptides too;
6) Refund all pre-payment(if pre-pay us) if we failed to synthesize any of them;
7) After-sale service: Contact us anytime if you have any problem when you use the peptides, and we will reply you as soon as possible.
AD
AD

Latest product

AD